Metabolic / Weight Loss
Learning tools for metabolism, body composition, appetite regulation, fat metabolism, and energy balance.
5-Amino-1MQ
Small-molecule NNMT inhibitor studied for adipose-tissue energy metabolism, NAD+/SAM preservation, and body-composition research in preclinical obesity models.
AOD-9604
Synthetic C-terminal hGH fragment (modified 177-191) studied for lipolysis, anti-lipogenesis, and fat-metabolism research, generally well tolerated in human trials but did not reach obesity-drug efficacy.
Dual Regulator DIA-39-C20
Catalogue identifier for Tirzepatide, a dual GIP/GLP-1 receptor agonist with strong human clinical evidence for chronic weight management, type 2 diabetes, and obstructive sleep apnea in adults with obesity.
Single Regulator SIA-31-C18
Catalogue identifier for Semaglutide, a GLP-1 receptor agonist with strong human clinical evidence for appetite regulation, glycemic control, chronic weight management, and cardiovascular risk reduction.
Triple Regulator TIA-39-C20 /Retatrutide
Triple incretin pathway research research overview.
SLU-PP-332
Synthetic pan-ERR (α/β/γ) agonist studied as an exercise-mimetic, preclinical evidence for mitochondrial function, fatty acid oxidation, endurance, and metabolic syndrome models. Investigational; published research notes limited oral bioavailability.
Semaglutide
GLP-1 receptor agonist for glucose regulation and weight loss research overview.
Tirzepatide
Dual GIP and GLP-1 receptor agonist for weight loss and glucose control research overview.
Retatrutide
Triple GLP-1, GIP, and glucagon receptor agonist research research overview.